Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01253421 · ClinicalTrials.gov registry record · Phase 1
The Effects of Dopamine on Reward Processing
A Phase 1 study, sponsored by Mclean Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 159
- Enrollment target
NCT01253421: Completed Phase 1 study, sponsored by Mclean Hospital.
NCT01253421 is a Phase 1 study that has completed, run by Mclean Hospital. The registered enrollment target is 159 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (165% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01253421, a Phase 1 study, has completed, sponsored by Mclean Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 159 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effects of a single low dose of the D2/D3 antagonist amisulpride on reward processing. More generally, this study will test the role of dopamine (a naturally occurring brain chemical) in depression. Hypotheses: Administration of a single low dose of the D2/D3 antagonist amisulpride will (1) improve performance in a behavioral task assessing learning from feedback and (2) boost activation in reward-related brain regions.
Primary Outcome
This statistic shows the effect (beta) that the combination of diagnosis and drug has on the ability to learn from rewards during a Probabilistic Selection Task (PST). A higher effect size indicates greater ability to learn from reward trials.
Interventions
- DRUG placebo
- DRUG amisulpride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2012-02 |
| Est. Completion | 2016-05 |
| Phase | Phase 1 |
What the finished NCT01253421 record still lists
NCT01253421 is an interventional study that assigns participants to a tested intervention. The registered 159 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (165% higher).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01253421 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01253421 about?
NCT01253421 is a clinical study titled "The Effects of Dopamine on Reward Processing". The purpose of this study is to evaluate the effects of a single low dose of the D2/D3 antagonist amisulpride on reward processing. More generally, this study will test the role of dopamine (a naturally occurring brain chemical) in depression. Hypotheses: Administration of a single low dose of the...
What is the current status of trial NCT01253421?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 159 participants. The study started on 2012-02. Estimated completion is 2016-05.
What interventions are being tested in trial NCT01253421?
The interventions under investigation include: placebo (DRUG), amisulpride (DRUG).
Who is sponsoring clinical trial NCT01253421?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01253421's enrollment target sits among peer trials
159 346th of 2000 higher than 1,653 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05267626 · 159 participants · Phase 1
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- NCT06321575 · 159 participants · NA
The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)
- NCT06729151 · 159 participants
Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in Patients With Bladder Pain Syndrome
- NCT07023731 · 159 participants · Phase 1
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia